Participated · Series A · Oct 2025

Lila Sciences develops an AI-driven platform that trains models on scientific literature across material sciences, chemistry and life sciences and generates experimental hypotheses. The company pairs those model outputs with laboratory setups to experimentally validate and close the loop between prediction and reproducible results. Reporting says Lila aims for a domain‑crossing, general-purpose science enablement stack rather than narrowly focused tools. Financially, it has completed a reported $200 million seed, emerged from stealth last year, and closed a $350 million Series A in October that lifted its valuation above $1.3 billion. Current reporting describes Lila negotiating an approximately $2 billion financing to scale compute, inference and laboratory capacity and to accelerate partner programs. The firm's growth narrative emphasizes standardizing experiment and feedback loops to make discovery repeatable and scalable.

Participated · Series B · Mar 2025

Ampersand Biomedicines is a Boston, MA-based multi-product platform company developing smart medicines. Its computationally empowered Address, Navigate, Determine (AND)™ platform identifies ideal addresses for drug localization and informs the design of AND-Body™ Therapeutics. AND-Body Therapeutics are designed to localize to intended targets and conditionally actuate biology to treat disease, enabling improved target engagement while limiting on-target, off-tissue side effects. The company raised $65M in Series B financing from backers that include Ampersand’s founder, Flagship Pioneering, Eli Lilly & Company and additional new investors to accelerate its initial pipeline. Its initial programs include candidates in immuno-inflammation and immuno-oncology, both planned to enter IND-enabling studies in 2025. The company is led by CEO Jason Gardner. Ampersand Biomedicines developed an Address, Navigate, Design (AND) platform that analyzes RNA transcript data across the human body to find disease-specific molecular "addresses" for targeting drugs. The company pairs a "localizer" that binds an address with an "actuator" carrying therapeutic effect, and actuators can be small molecules, proteins, lipid nanoparticles, or nucleic acids. Ampersand has generated or acquired transcriptomic datasets, validated its address map in multiple preclinical tests, and is conducting animal testing to further validate localization and therapeutic activity. The startup emerged from stealth as it progresses toward human testing and plans to expand headcount (currently 33 employees). Founded within Flagship Pioneering's lab incubator in 2020, Ampersand is positioned to pursue partnerships where larger companies may use its technology or develop drugs originating from its platform. The company aims to address on-target, off-tissue toxicity and to enable therapies against targets previously considered undruggable due to promiscuous biodistribution.

Participated · Equity · Jan 2025

Inari develops seed technologies that combine AI-powered predictive design with a multiplex gene editing toolbox to deliver step-change soybean, corn and wheat products. The company is singularly focused on seed technology for large-acre crops and operates an asset-light business model intended to support, not rival, seed companies. Inari reports strong performance from its first-generation products and progress toward commercialization, generating interest from seed companies both within and outside the U.S. Financially, the company completed a $144 million fundraise and has cumulative equity raised of more than $720 million. Founded by Flagship Pioneering in 2016, Inari is based in Cambridge, Mass., with additional sites in West Lafayette, Ind., and Ghent, Belgium, and employs more than 300 people. The new capital is intended to underpin long-term growth as Inari works to bring high-performing products to market at global scale. Inari develops seeds aimed at a more sustainable, nature‑positive food system by combining AI‑powered predictive design with a multiplex gene‑editing toolbox. The company intends to use the new funds to further advance its technology platform and accelerate product commercialization. Inari has a team of more than 300 employees and is led by CEO Ponsi Trivisvavet. Founded by Flagship Pioneering in 2016, the company is based in Cambridge, MA, with additional sites in West Lafayette, Ind., and Ghent, Belgium. The business recently closed a $103M funding round, bringing its total capital raised to $575M. Inari pairs AI-powered predictive design with multiplex gene editing to engineer seeds for the commercial agriculture market. The company focuses on multiplex gene-edited seed technology and advancing product development to deliver new value to growers and supply chains. It plans to use the new capital to further its technology position and expand product development efforts. Inari completed a $124M Series E equity raise and also refinanced and upsized a loan agreement to access up to $60M in debt capital. Led by CEO Ponsi Trivisvavet, the company was founded by Flagship Pioneering and has grown to more than 230 employees. Inari is based in Cambridge, Mass., with additional sites in West Lafayette, Ind., and Ghent, Belgium. Inari has developed a platform that uses predictive design and artificial intelligence to build deep understanding of genes and to design blueprints for combinations of gene‑editing tools that enable multiple edits within a single genome. Those edits produce seeds that aim to increase crop yield while reducing agriculture's footprint. The company focuses on product development for corn and soybeans in North and South America and plans to use the new funds to accelerate advancements across its science platform and product development. Inari raised $208M in a Series D that brought its cumulative equity raised to more than $352M. The round was co‑led by Flagship Pioneering with participation from Alexandria Venture Investments, Investment Corporation of Dubai, Banque Pictet (on behalf of clients), Rivas Capital, and new investors G Squared and Pavilion Capital. Founded by Flagship Pioneering in 2016, Inari is based in Cambridge, Massachusetts, with additional sites in West Lafayette, Indiana, and Ghent, Belgium. The company is led by CEO Ponsi Trivisvavet and has a team of more than 180 employees. Inari develops next-generation seeds using genetic technologies and data science. Led by CEO Ponsi Trivisvavet, the company focuses on gene-edited crops designed to reduce the natural resources required to grow food. It intends to use recent capital to accelerate development and commercialization of those gene-edited crops. The company was founded by Flagship Pioneering in 2016. Inari is headquartered in Cambridge, Mass., with additional sites in West Lafayette, Ind., and Ghent, Belgium. The company recently completed an $89M equity raise and has secured a $45M loan facility to support its plans.

Led · Equity · May 2024

Prologue Medicines develops therapeutics by mining the viral proteome using its proprietary DELVE™ Platform, which combines computation and high-throughput biology. The DELVE Platform contains a large database of viral protein structures layered with data from known human proteins and annotated, predicted viral proteins. Prologue applies learned rules of natural viral evolution and machine learning to identify and create enhanced therapeutic proteins with properties that can modulate human physiology. The company aims to build a pipeline of medicines across immunological, oncology, and metabolic indications. Flagship Pioneering initially committed $50 million to advance Prologue’s platform and pipeline. Prologue was founded by Flagship Pioneering in 2021 and is based in Cambridge, Mass.

Led · Equity · Nov 2023

Quotient Therapeutics develops a Somatic Genomics platform that systematically studies genetic variation and the evolution of cells to reveal links between genes and disease. The platform analyzes natural selection at the cellular level via four steps: phenotyping of cells from clinical tissue samples, isolation, single-cell genotyping, and computation. Created by Flagship scientists in partnership with geneticists at the Wellcome Sanger Institute and the University of Texas Southwestern, the platform identifies naturally selected genes, proteins, and pathways as prospective therapeutic targets. Quotient aims to enable discovery of first-in-class drugs across a broad range of modalities and therapeutic areas, including immune, cardiometabolic, infectious, oncology, neurodegenerative, rare disease, and aging. The company is led by Geoffrey von Maltzahn, with co-founders and senior leaders from Flagship, the Wellcome Sanger Institute, and UT Southwestern. Quotient raised $50M in initial funding to advance development of its platform.